Puma Biotechnology (PBYI) Change in Receivables (2017 - 2026)

Puma Biotechnology (PBYI) has 10 years of Change in Receivables data on file, last reported at -$27.3 million in Q1 2026.

• Quarterly Change in Receivables fell 312.39% year-over-year to -$27.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $582000.0 (up 238.37% YoY) and the FY2025 annual result came in at $21.3 million, up 230.2% from the prior year.
• Change in Receivables slipped to -$27.3 million in Q1 2026, from $20.1 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $26.5 million in Q3 2024 to a low of -$27.3 million in Q1 2026.
• A 5-year average of -$364529.4 and a median of $376000.0 in 2025 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2022 — Change in Receivables plunged 992.2% — and 2024, when it surged 1243.78%.
• Tracing PBYI's Change in Receivables over 5 years: stood at $12.3 million in 2022, then soared by 56.09% to $19.2 million in 2023, then tumbled by 219.76% to -$23.0 million in 2024, then surged by 187.23% to $20.1 million in 2025, then plunged by 236.02% to -$27.3 million in 2026.
• The last three Change in Receivables figures came in at -$27.3 million (Q1 2026), $20.1 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.